LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Integra LifeSciences Holdings Corp

Ouvert

SecteurSoins de santé

11.27 4.35

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.2

Max

11.46

Chiffres clés

By Trading Economics

Revenu

479M

-5.4M

Ventes

-14M

402M

Marge bénéficiaire

-1.344

Employés

4,396

EBITDA

526M

54M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+14.84% upside

Dividendes

By Dow Jones

Prochains Résultats

26 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-404M

852M

Ouverture précédente

6.92

Clôture précédente

11.27

Sentiment de l'Actualité

By Acuity

78%

22%

321 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Integra LifeSciences Holdings Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 févr. 2026, 23:21 UTC

Acquisitions, Fusions, Rachats

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 févr. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 févr. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15 févr. 2026, 23:06 UTC

Résultats

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 févr. 2026, 23:04 UTC

Résultats

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 févr. 2026, 23:04 UTC

Résultats

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 févr. 2026, 23:01 UTC

Résultats

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 févr. 2026, 23:01 UTC

Résultats

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 févr. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 févr. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 févr. 2026, 22:52 UTC

Acquisitions, Fusions, Rachats

Qube Shareholders to Receive A$5.20/Share in Cash

15 févr. 2026, 22:52 UTC

Acquisitions, Fusions, Rachats

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 févr. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 févr. 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 févr. 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 févr. 2026, 22:14 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 févr. 2026, 22:14 UTC

Acquisitions, Fusions, Rachats

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 févr. 2026, 20:48 UTC

Résultats

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 févr. 2026, 20:47 UTC

Résultats

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 févr. 2026, 20:46 UTC

Résultats

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 févr. 2026, 20:45 UTC

Résultats

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 févr. 2026, 20:44 UTC

Résultats

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 févr. 2026, 20:44 UTC

Résultats

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 févr. 2026, 20:43 UTC

Résultats

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 févr. 2026, 20:42 UTC

Résultats

BlueScope Net Debt A$2.2 Million at Dec. 31

15 févr. 2026, 20:42 UTC

Résultats

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 févr. 2026, 20:41 UTC

Résultats

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 févr. 2026, 20:40 UTC

Résultats

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 févr. 2026, 20:40 UTC

Résultats

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 févr. 2026, 20:39 UTC

Résultats

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Comparaison

Variation de prix

Integra LifeSciences Holdings Corp prévision

Objectif de Prix

By TipRanks

14.84% hausse

Prévisions sur 12 Mois

Moyen 13 USD  14.84%

Haut 13 USD

Bas 13 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

2 ratings

0

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

12.75 / 16.41Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

321 / 351Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Integra LifeSciences Holdings Corp

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
help-icon Live chat